Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment
- 31 August 2010
- journal article
- research article
- Published by Elsevier BV in Neurobiology of Aging
- Vol. 31 (8), 1452-1462.e2
- https://doi.org/10.1016/j.neurobiolaging.2010.04.011
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health and Care Research
- Alzheimer's Research Trust
- Medical Research Council
- Technology Strategy Board (TP1838A)
This publication has 40 references indexed in Scilit:
- Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's diseaseNeuroImage, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjectsNeuroImage, 2009
- Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selectionNeuroImage, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's diseaseBrain, 2009
- Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCINeurobiology of Aging, 2008
- Covariate adjustment for two‐sample treatment comparisons in randomized clinical trials: A principled yet flexible approachStatistics in Medicine, 2008
- MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkersBrain, 2008
- Global prevalence of dementia: a Delphi consensus studyThe Lancet, 2005